Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,124.00
Ask: 12,128.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - AstraZeneca Plc

22 May 2014 15:08

RNS Number : 8513H
Franklin Resources, Inc
22 May 2014
 

FORM 8.3

 

 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed:

Franklin Resources, Inc.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

AstraZeneca Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

21 May 2014

 

(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

Yes

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Amendment to section (1) and total

Class of relevant security:

 

ORD GBP.25

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

11,628,581

0.92%

(2) Derivatives (other than options):

(3) Options and agreements to purchase/sell:

 

1,320,500

 

0.10%

TOTAL:

12,949,081

1.03%

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

ORD GBP.25

Purchase

10,680

44.3997 GBP

ORD GBP.25

Sale

174,800

44.2907 GBP

ADR

Sale

11,000

74.3000 USD

 

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

ADR

call option

sell short

1,205 calls (120,500 securities)

85.00 USD

American

21/06/2014

0.966900USD

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

YES

 

Date of disclosure:

22 May 2014

Contact name:

Lucrece Le Gal

Telephone number:

+1 (954) 762-4258

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL FORM 8 (OPEN POSITIONS)

 

DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the "Code")

 

 

1. KEY INFORMATION

 

Identity of person whose open positions are being disclosed:

Franklin Resources, Inc.

Name of offeror/offeree in relation to whose relevant securities the disclosure relates:

AstraZeneca Plc

 

2. OPTIONS AND DERIVATIVES

 

Class of relevant security

Product description e.g. call option

Written or purchased

Number of securities to which option or derivative relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

ORD GBP.25

Call options

purchase

500 calls (500,000 securities)

48.00

GBP

American

20/06/2014

ORD GBP.25

Put options

sell short

700 puts (700,000 securities)

45.00 GBP

American

20/06/2014

ADR

Call options

sell short

1,205 calls (120,500 securities)

85.00

USD

American

21/06/2014

 

3. AGREEMENTS TO PURCHASE OR SELL ETC.

 

Full details should be given so that the nature of the interest or position can be fully understood:

 

 

 

 

 

 

It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to contracts for differences ("CFDs") or spread bets.

 

The currency of all prices and other monetary amounts should be stated.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETBSGDULGDBGSD
Date   Source Headline
5th Sep 20227:05 amRNSForxiga approved in China for CKD
5th Sep 20227:00 amRNSImfinzi approved in US for biliary tract cancer
1st Sep 20223:00 pmRNSTotal Voting Rights
30th Aug 20221:00 pmRNSEvusheld approved for COVID-19 in Japan
30th Aug 20227:01 amRNSFarxiga shows CV mortality benefit across EF range
30th Aug 20227:00 amRNSFarxiga reduced risk of CV death or worsening HF
25th Aug 20227:10 amRNSUltomiris approved in Japan for gMG
25th Aug 20227:05 amRNSTagrisso approved in Japan for early lung cancer
25th Aug 20227:00 amRNSLynparza approved in Japan for early breast cancer
16th Aug 20227:00 amRNSLynparza granted FDA priority review for PROpel
15th Aug 20227:00 amRNSEnhertu improved PFS in mBC in DESTINY-Breast02
12th Aug 20227:00 amRNSEnhertu approved in US for HER2-mutant NSCLC
11th Aug 20227:00 amRNSAcquisition of TeneoTwo completed
8th Aug 20227:10 amRNSEnhertu approved in the US for HER2-low mBC
4th Aug 20227:00 amRNSLynparza approved in EU for early breast cancer
1st Aug 20225:00 pmRNSDirector/PDMR Shareholding
1st Aug 20223:05 pmRNSDirector/PDMR Shareholding
1st Aug 20223:00 pmRNSTotal Voting Rights
29th Jul 20227:01 amRNSChair succession
29th Jul 20227:00 amRNSHalf-year Report
25th Jul 20227:10 amRNSTezspire recommended for EU approval in asthma
25th Jul 20227:05 amRNSUltomiris recommended for EU approval for gMG
25th Jul 20227:00 amRNSEnhertu granted Priority Review for HER2-low mBC
19th Jul 20227:00 amRNSEnhertu approved in EU for HER2-positive mBC
5th Jul 20227:00 amRNSAstraZeneca to acquire TeneoTwo and T cell engager
1st Jul 20223:00 pmRNSTotal Voting Rights
30th Jun 20227:00 amRNSImfinzi improved pCR in resectable lung cancer
27th Jun 20227:05 amRNSEnhertu recommended for breast cancer EU approval
27th Jun 20227:00 amRNSLynparza recommended in EU for early breast cancer
21st Jun 20227:00 amRNSEplontersen Ph III trial met co-primary endpoints
6th Jun 20227:00 amRNSEnhertu efficacy results in HER2-low breast cancer
1st Jun 20223:00 pmRNSBlock listing Interim Review
1st Jun 20223:00 pmRNSTotal Voting Rights
20th May 20224:00 pmRNSDirector/PDMR Shareholding
9th May 20221:00 pmRNSAppointment of joint corporate brokers
6th May 20224:00 pmRNSDirector/PDMR Shareholding
5th May 20227:10 amRNSEnhertu approved in US for 2L HER2+ breast cancer
5th May 20227:05 amRNSFarxiga HFpEF Phase III trial met primary endpoint
5th May 20227:00 amRNSUltomiris NMOSD Ph. III trial met primary endpoint
4th May 20227:00 amRNSImfinzi combo granted Priority Review for BTC
3rd May 20223:00 pmRNSTotal Voting Rights
29th Apr 20225:30 pmRNSResult of AGM
29th Apr 20227:05 amRNSAstraZeneca plans new R&D centre in Massachusetts
29th Apr 20227:00 amRNSFirst quarter 2022 results
28th Apr 20227:00 amRNSUltomiris approved in the US for adults with gMG
27th Apr 20227:00 amRNSEnhertu granted BTD for HER2-low breast cancer
25th Apr 20227:00 amRNSTremelimumab US Priority Review for Imfinzi combo
19th Apr 20227:00 amRNSEnhertu granted Priority Review for HER2m NSCLC
1st Apr 20223:00 pmRNSTotal Voting Rights
29th Mar 20227:00 amRNSOndexxya approved in Japan for FXai reversal

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.